Mail

UK markets closed

FTSE 100
8,139.83
+60.97(+0.75%)
FTSE 250
19,824.16
+222.18(+1.13%)
AIM
755.46
+2.34(+0.31%)
GBP/EUR
1.1668
+0.0012(+0.10%)
GBP/USD
1.2471
-0.0040(-0.32%)
Bitcoin GBP
50,919.51
-487.48(-0.95%)

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

1.7200

-0.1400

(-7.53%)

As of 11:45AM EDT. Market open.

Currency in USD

Valuation measures⁴

Market cap (intra-day)	12.31M
Enterprise value	-705.83k
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	N/A
Price/book (mrq)	1.12
Enterprise value/revenue	N/A
Enterprise value/EBITDA	0.04

Trading information

Stock price history

Beta (5Y monthly)	1.20
52-week change ³	-43.35%
S&P500 52-week change ³	21.08%
52-week high ³	4.3500
52-week low ³	0.7900
50-day moving average ³	2.1738
200-day moving average ³	1.8095

Share statistics

Avg vol (3-month) ³	103.9k
Avg vol (10-day) ³	72.11k
Shares outstanding ⁵	6.48M
Implied shares outstanding ⁶	6.48M
Float ⁸	5.57M
% held by insiders ¹	13.85%
% held by institutions ¹	9.58%
Shares short (15 Apr 2024) ⁴	54.57k
Short ratio (15 Apr 2024) ⁴	1.21
Short % of float (15 Apr 2024) ⁴	0.98%
Short % of shares outstanding (15 Apr 2024) ⁴	0.84%
Shares short (prior month 15 Mar 2024) ⁴	30.25k

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	1:6
Last split date ³	30 Jun 2023

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	0.00%
Operating margin (ttm)	-440,356,600.00%

Management effectiveness

Return on assets (ttm)	-63.67%
Return on equity (ttm)	-118.88%

Income statement

Revenue (ttm)	260.5k
Revenue per share (ttm)	0.05
Quarterly revenue growth (yoy)	-100.00%
Gross profit (ttm)	N/A
EBITDA	-19.91M
Net income avi to common (ttm)	-19.03M
Diluted EPS (ttm)	-3.5700
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	13.25M
Total cash per share (mrq)	2.05
Total debt (mrq)	622k
Total debt/equity (mrq)	5.67%
Current ratio (mrq)	4.13
Book value per share (mrq)	1.77

Cash flow statement

Operating cash flow (ttm)	-18.09M
Levered free cash flow (ttm)	-12.17M